CTLA4 and melanoma: Gopal et al. demonstrated that targeting GLS with CB-839 in melanoma cells, in combination with anti-PD-1 and anti-CTLA4 antibodies, enhanced the therapeutic efficacy of immune checkpoint blockade (ICB)56.